Anthera Pharmaceuticals, Inc. (ANTH) Lowered to Hold at Zacks Investment Research
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
A number of other analysts have also weighed in on ANTH. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a research note on Tuesday, September 19th. ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $1.75 price objective (down previously from $2.25) on shares of Anthera Pharmaceuticals in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $5.11.
Anthera Pharmaceuticals (NASDAQ ANTH) traded down 5.73% during midday trading on Tuesday, reaching $1.48. 787,661 shares of the company’s stock were exchanged. The stock’s market capitalization is $16.14 million. The stock’s 50-day moving average is $1.52 and its 200-day moving average is $1.47. Anthera Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $2.81.
Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.09) by $1.12. On average, equities analysts forecast that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current year.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/24/anthera-pharmaceuticals-inc-anth-lowered-to-hold-at-zacks-investment-research.html.
An institutional investor recently raised its position in Anthera Pharmaceuticals stock. UBS Group AG raised its stake in shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by 9.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 375,989 shares of the biopharmaceutical company’s stock after purchasing an additional 33,901 shares during the period. UBS Group AG’s holdings in Anthera Pharmaceuticals were worth $160,000 at the end of the most recent quarter. Institutional investors and hedge funds own 27.03% of the company’s stock.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.